The BioCentury Show

BioCentury Podcasts
  • 4.6 (11)
  • LIFE SCIENCES
  • UPDATED BIWEEKLY

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast.

  1. Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next

    5D AGO

    Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next

    Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capital, alongside PE firms’ increasing ability to conduct the technical diligence required for investments once considered too risky for their models. In conversation with The BioCentury Show's Stephen Hansen, Bain Capital’s Adam Koppel discussed the evolution of private equity's interest in biotech, Bain’s prioritization scheme for scaled investments and his outlook for the capital markets in the year ahead. View full story: https://www.biocentury.com/article/657997 #PrivateEquity #BiotechDeals #LifeSciencesInvesting #GrowthEquity #BiopharmaMarkets 00:00 - Introduction 01:57 - PE's Evolution in Biotech 06:58 - Bain's Priorities 11:24 - Structuring Deals 18:23 - Capital Market Conditions 24:03 - Environment for Private Companies 27:08 - IPO Outlook

    37 min
  2. Ep. 99 – Stelios Papadopoulos on Biotech’s Long View: Pricing Pressure, China & Big Pharma

    12/19/2025

    Ep. 99 – Stelios Papadopoulos on Biotech’s Long View: Pricing Pressure, China & Big Pharma

    In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, but the level of anxiety in biotech doesn’t reflect the “extraordinary science, the likes of which we’ve never seen — and it’s getting better,” said Papadopoulos on The BioCentury Show. Papadopoulos is one of the long-term leading voices of biopharma, recognized for his influence in shaping the industry. Former chair of Biogen and current chair of Exelixis, with roles on several boards, and a background of nearly two decades as an investment banker, he brings a long view to how the industry has grown and the forces driving where it is headed. Tune in to hear his take on the financing environment for biotechs, company building, pricing pressure, innovation from China, and the future of big pharmas, in conversation with Editor in Chief Simone Fishburn. View full story: https://www.biocentury.com/article/657910 #BiotechOutlook #DrugPricing #ChinaBiotech #BigPharma #BiopharmaStrategy 00:00 - Introduction 02:00 - Financing Environment 10:18 - Company Building 20:47 - Women in Biotech 25:38 - China, Korea & Europe 30:00 - Is Biotech Too Insular?

    38 min
  3. Ep. 98 - Inside Precision Oncology’s Next Chapter with Fore’s Bill Hinshaw

    12/05/2025

    Ep. 98 - Inside Precision Oncology’s Next Chapter with Fore’s Bill Hinshaw

    When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Biotherapeutics — he sees a precision oncology field transformed by technological ambition, yet still grappling with many of the structural challenges that defined its beginnings, now compounded by the difficulty of positioning therapies within an ever more complex treatment landscape. Gleevec proved the power of targeting a genomic driver, but the healthcare system around it was far from ready. “We weren’t able to fulfill the promise as fast as we wanted to until that scaling happened,” Hinshaw told The BioCentury Show — a reminder that even today, precision medicines succeed or fail based not only on their biology but on the infrastructure that enables patients to access them. Hinshaw sat down with Executive Editor Selina Koch on The BioCentury Show to discuss what’s changed in precision oncology, what’s stayed the same, and how he’s applying those lessons to steer Fore’s BRAF-focused program. View full story: https://www.biocentury.com/article/657768 #PrecisionOncology #BRAFAlterations #NGSTesting #MasterProtocol #TargetedTherapies 00:00 – Introduction 00:47 – Precision Medicine’s Evolution 09:22 – Zeroing in on Subtypes 17:59 – Fore’s BRAF Inhibitor 26:38 – Fore’s Development Approach 32:01 – Moving from Pharma to Biotech

    38 min
  4. Popular Episode - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future

    11/27/2025

    Popular Episode - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future

    This is a previously recorded episode of The BioCentury Show from September 5, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. If you could redesign FDA from the ground up, what would it look like? That’s the fundamental question underlying the 2025 BioCentury Back to School essay, authored by BioCentury Washington Editor Steve Usdin, who has been a leading voice on regulation and policy for over two decades. The topic is especially meaningful in this era of FDA turmoil, when regulatory risk has piled on top of the market pullback, making biotech appear an unusually hazardous domain for investors. But while the current landscape has underscored the need, FDA reform has been on the table long before this administration came into power. On this edition of The BioCentury Show, Usdin and Editor in Chief Simone Fishburn discuss the key arguments, and some specific concepts, within Back To School, which reimagines the U.S. drugs regulator. View full story: https://www.biocentury.com/article/656928 #FDA #DrugRegulation #Biopharma #LifeSciences #Biotech #PublicTrust 00:00 - Introduction 02:39 - Restructuring FDA 18:08 - A Learning Regulatory Agency 27:54 - Global View 31:09 - Talent 32:59 - User Fees

    39 min
  5. Ep. 97 – From NIH to Industry: Zerhouni Warns Policy & Rhetoric Threaten U.S. Science

    11/14/2025

    Ep. 97 – From NIH to Industry: Zerhouni Warns Policy & Rhetoric Threaten U.S. Science

    Elias Zerhouni personifies the American dream. He arrived in the U.S. from Algeria as a young man with a couple of hundred dollars in his pocket. Talent, ambition and hard work propelled him into a successful academic career. In 2002, he was nominated and confirmed as NIH director, and later he served in senior positions in the biopharma industry. That trajectory “would be almost impossible” today, he told BioCentury Washington Editor Steve Usdin on The BioCentury Show. Anti-immigration policies, underfunding of basic research, and attacks on philanthropy have made the U.S. an unattractive destination for anyone hoping to follow his path, Zerhouni said. Zerhouni also discussed reasons for optimism about life sciences in the U.S., the difficulty of fixing drug pricing, and his time at Sanofi. View full story: https://www.biocentury.com/article/657591 #NIH #BiomedicalInnovation #ImmigrationPolicy #Biopharma #LifeSciences #HealthcareReform #MedicalResearch 01:09 - The American Dream & Science 05:51 - Zerhouni at NIH 09:40 - Loss of Trust 16:53 - Vaccine Policy 20:12 - Zerhouni in Industry 23:20 - Drug Pricing

    34 min
  6. Ep. 96 – From Pharma Partnering to Biotech CEO: Sophie Kornowski on Boston Pharma’s Playbook

    10/31/2025

    Ep. 96 – From Pharma Partnering to Biotech CEO: Sophie Kornowski on Boston Pharma’s Playbook

    It took Sophie Kornowski under four years as CEO of Boston Pharma to bring it from a pipeline full of in-licensed assets to an acquisition by GSK for about $2 billion in total deal value for a single MASH program. Though her first gig as a biotech CEO, Kornowski’s success was built on her years of experience as head of partnering at Roche. She discussed that pivot and the value of rolling your sleeves up on the latest episode of The BioCentury Show. View full story: https://www.biocentury.com/article/657446 #BiotechLeadership #DrugDevelopment #PharmaDeals #BiotechCEO #StartupSuccess #LifeSciences #MetabolicDisease #PharmaInnovation 00:00 - Introduction 01:15 - Becoming a Biotech CEO 11:40 - MASH 18:15 - First v. Best in Class 24:10 - GSK Deal

    32 min
  7. Ep. 95 - Kymera CEO Nello Mainolfi: Matching Degrader Chemistry to the Problem

    10/16/2025

    Ep. 95 - Kymera CEO Nello Mainolfi: Matching Degrader Chemistry to the Problem

    Kymera Therapeutics has a clear mission: to transform immunology with targeted protein degraders that enable “oral drugs with biologics-like activity,” CEO Nello Mainolfi told The BioCentury Show. A pioneer in one of biopharma’s most closely watched new therapeutic modalities, Kymera is now over nine years into its story, with multiple pharma partnerships and a wholly owned pipeline, including a STAT6 degrader that produced promising data in June. In conversation with BioCentury’s Selina Koch, Mainolfi discusses the appeal of degraders, the rationale for choosing glues or heterobifunctional degraders and how to prove a new modality on a new target without incurring biology risk. View full story: https://www.biocentury.com/article/657297 #ProteinDegradation #DrugDiscovery #MolecularGlues #HeterobifunctionalDegraders #Immunology #RationalDrugDesign #BiotechInnovation 00:00 - Introduction 01:07 - Degraders' Appeal 07:22 - Glue vs. Heterobifunctional 16:12 - Translating a New Modality 24:14 - Partnerships

    32 min
  8. Ep. 94 - Frazier's James Li on China’s Rapidly Evolving Biotech Deal Landscape

    10/03/2025

    Ep. 94 - Frazier's James Li on China’s Rapidly Evolving Biotech Deal Landscape

    The frenzy among Western companies to access China’s biotechnology innovation is remaking the landscape for cross-border dealmaking, with assets becoming more expensive and partnerships earlier and broader than ever before. That’s being driven by exceptional capital efficiency, access to patients and speed of development, said Frazier Life Sciences’ James Li on The BioCentury Show podcast. Among multinational companies, “every company has an army on the ground hunting for assets,” said Li, who has more than 30 years of biotech experience, as an investor, company builder and executive at an MNC and a biotech. View full story: https://www.biocentury.com/article/657156 #ChinaBiotech #Biopharma #CrossBorderDeals #LifeSciences #DrugDevelopment #HealthcareInnovation #BiotechInvesting 00:00 - Introduction  02:18 - Evolution of an Ecosystem  04:31 - NewCo Deals  10:30 - Japan, Korea  15:30 - Dealmaking

    30 min
See All (52)

Ratings & Reviews

4.6
out of 5
11 Ratings

About

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast.

Information

More From BioCentury Podcasts

You Might Also Like